EGFR-TKI for Advanced NSCLC Market, Global Outlook and Forecast 2024-2031

Report ID: 1133797 | Published Date: Jan 2025 | No. of Page: 65 | Base Year: 2024 | Rating: 3.7 | Webstory: Check our Web story

EGFR tyrosine kinase inhibitors (TKIs) are molecules that could inhibt EGFR function through binding. Its monotherapy as first-line treatment can benefit NSCLC patients harbouring EGFR mutations.
This report contains market size and forecasts of EGFR-TKI for Advanced NSCLC in Global, including the following market information:
Global EGFR-TKI for Advanced NSCLC Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global EGFR-TKI for Advanced NSCLC market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Gefitinib Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of EGFR-TKI for Advanced NSCLC include Henan DaKen Chemical, Capot Chemical Co.,Ltd., Chemwill Asia Co.,Ltd., MSN Labs, Sun Pharma, Amadis Chemical, Chongqing Chemdad Co., Ltd, Mylan and Alchem Pharmtech,Inc.. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the EGFR-TKI for Advanced NSCLC companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global EGFR-TKI for Advanced NSCLC Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global EGFR-TKI for Advanced NSCLC Market Segment Percentages, by Type, 2021 (%)
Gefitinib
Erlotinib
Afatinib
Global EGFR-TKI for Advanced NSCLC Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global EGFR-TKI for Advanced NSCLC Market Segment Percentages, by Application, 2021 (%)
Combination Therapy
Mono Therapy
Global EGFR-TKI for Advanced NSCLC Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global EGFR-TKI for Advanced NSCLC Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies EGFR-TKI for Advanced NSCLC revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies EGFR-TKI for Advanced NSCLC revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Henan DaKen Chemical
Capot Chemical Co.,Ltd.
Chemwill Asia Co.,Ltd.
MSN Labs
Sun Pharma
Amadis Chemical
Chongqing Chemdad Co., Ltd
Mylan
Alchem Pharmtech,Inc.

Frequently Asked Questions
EGFR-TKI for Advanced NSCLC Market In Global report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
EGFR-TKI for Advanced NSCLC Market In Global report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
EGFR-TKI for Advanced NSCLC Market In Global report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports